Highest-materiality recent filing
iAnthus Q1 revenue $33.5M, net loss $14.3M; Adjusted EBITDA $3.4M
Revenue of $33.5M, down $4.6M YoY and $1.8M sequentially from Q4 2025.
iAnthus FY2025 revenue down 14.1% to $144M; net loss widens to $40.2M
FY2025 revenue $144.0M vs $167.6M prior year; net loss $40.2M vs $7.6M loss.
iAnthus Q3 revenue falls 12% YoY to $35.4M; adjusted EBITDA halved to $2.5M
Revenue $35.4M, down $4.9M (-12%) from Q3 2024; gross profit $15.6M vs $18.1M; gross margin 44.0%.
iAnthus Q2 2025 revenue $35.2M (-18% YoY); net loss $18.7M
Revenue of $35.2M, down $7.8M YoY and $2.9M sequentially.
iAnthus Q1 2025 revenue $38.1M (-8% YoY); net income $5.1M, gross margin 49.5%
Revenue of $38.1M, down $3.4M from Q1 2024 and down $4.6M from Q4 2024.
iAnthus reports FY2024 revenue $167.6M (+5.2% YoY); net loss narrows to $7.6M
FY2024 revenue $167.6M (+5.2% YoY); gross profit $75.1M (+18.9%); gross margin 44.8% (+516 bps).
iAnthus Q3 revenue $40.3M (-6.1% YoY); net loss narrows to $11.6M
Revenue $40.3M, down 6.1% YoY and 6.3% sequentially from Q2 2024.
iAnthus sells 3 AZ dispensaries, 2 facilities to Sonoran Roots for $36.5M
Consideration of $36.5M: $20M cash at closing plus $16.5M promissory note at 6% interest over 66 months.
iAnthus Q2 revenue $43M (+11% YoY); net loss narrows to $9.8M from $20.1M
Revenue of $43.0M, up 3.5% sequentially and 11.1% YoY.
iAnthus Q1 2024 revenue $41.6M (+13% YoY); net loss narrows to $14.0M
Revenue of $41.6M, up 13.1% YoY and 1.7% sequentially; gross margin 41.4%.
iAnthus FY2023 revenue $159.2M, down 2.4%; net loss narrows to $76.6M
Revenue $159.2M (down 2.4% YoY); gross margin 39.7% (down 590bps from 45.6%).
iAnthus extends $15.8M bridge notes maturity to Feb 2026, pays 10% fee in shares
Maturity of secured bridge notes extended from Feb 16, 2024 to Feb 16, 2026.
iAnthus restates Q3 2023 results; inventory and liabilities overstated due to consolidation error
Audit committee determined Sept 30, 2023 financials were materially misstated; reliance withdrawn.
iAnthus settles Hi-Med lawsuit by issuing 20M common shares; claim dismissed with prejudice
iAnthus issued 20 million common shares to Hi-Med to settle litigation over a $5M unsecured debenture.
iAnthus Q2 revenue $38.7M, down 11% YoY; adjusted EBITDA turns negative $0.4M
Revenue $38.7M, up 5.2% sequentially but down 11.0% YoY from $43.5M.
iAnthus appoints Richard Proud as CEO; base salary $475K, RSUs of 3% fully diluted shares
Richard Proud appointed CEO and Board member, effective July 17, 2023.
iAnthus Q1 revenue $36.8M, down 14.1% YoY; net loss $18.6M
Revenue $36.8M, down 14.1% YoY and 2.2% sequentially; gross profit $15.5M, down 31% YoY.
iAnthus FY2022 revenue down 19.6% to $163.2M; net loss widens to $449.4M
Revenue $163.2M vs $203.0M in 2021; gross margin fell to 45.6% from 53.9%.
iAnthus extends maturity of $14M bridge notes to 2024; interest rate rises to 12%
Maturity of ~$14M senior secured bridge notes extended from Feb 2023 to Feb 2024.
iAnthus faces shareholder petition to set aside recap and replace board; company seeks dismissal
Michael Weisser filed application Nov 14, 2022 in BC Supreme Court to add secured and unsecured debenture holders as respondents.
iAnthus reports Q3 2022 revenue of $39.4M, net loss $22.0M, adjusted EBITDA loss $0.3M
Revenue $39.4M, down 10% sequentially and 20% YoY from $49.3M in Q3 2021.
iAnthus Q2 2022 net loss $373.6M on $316.6M debt extinguishment; revenue down 20% YoY
Revenue $43.5M, down 20% YoY; gross margin 45.2% vs 57.7% prior year.
iAnthus closes recapitalization; existing holders diluted to 2.75%, new $120M debentures issued
Issued 6.07B common shares to secured and unsecured lenders; existing shareholders reduced to 2.75% ownership.
Mass. cannabis commission clears iAnthus recapitalization milestone for Mayflower
Massachusetts CCC approved change of ownership application for Mayflower Medicinals on June 9, 2022, a key step in recapitalization.
iAnthus Q1 revenue $42.8M down 17% YoY; net loss $10.1M; liquidity constraints persist
Revenue of $42.8M, down 17% YoY and 10% sequentially; gross margin 52.6% improved QoQ but down YoY.
iAnthus appoints Robert Galvin as Interim CEO; Maryland & Florida approve recapitalization steps
Randy Maslow resigns as Interim CEO, President and Director effective May 6, 2022; remains consultant for 6 months.
iAnthus co-founder and Interim CEO Randy Maslow resigns, effective May 6, 2022
Randy Maslow resigns as Interim CEO, President, Board member and committee roles, effective May 6, 2022.
Revenue $203.0M up 34% from prior year; gross profit $111.3M (54.8% margin).
iAnthus closes acquisition of MPX New Jersey, adding medical cannabis license in NJ
iAnthus acquires 100% of MPX New Jersey LLC after NJ CRC approval on Jan 7, 2022; closed Feb 1, 2022.
Effective upon Mr. Ware’s appointment as the CFO, Justin Vu resigned as Chief Financial Officer of the Company as well as all other positions with the Company, its subsidiaries and its affiliates.
Effective April 29, 2026, iAnthus Capital Holdings, Inc. (the “Company”) appointed Jason Ware, age 52, as the Company’s Chief Financial Officer (the “CFO”).
On January 6, 2025, the Company appointed Mr. Vu, 41, as permanent Chief Financial Officer (“CFO”) of the Company.
On March 29, 2024, Mr. Philippe Faraut resigned as Chief Financial Officer of iAnthus Capital Holdings, Inc. (the “Company”) as well as all positions with the Company’s subsidiaries and its affiliates, effective as of April 5, 2024
The Company has appointed Justin Vu to serve as Interim Chief Financial Officer of the Company, effective as of the Resignation Date.
On March 11, 2024, John Paterson informed the board of directors (the “Board”) of iAnthus Capital Holdings, Inc. (the “Company”) of his resignation as a member of the Board and as a member of the Company’s audit committee effective immediately.
Effective October 11, 2023, Robert Galvin completed the transition out of his role as the Interim Chief Operating Officer of iAnthus Capital Holdings, Inc.
Effective July 17, 2023, iAnthus Capital Holdings, Inc. (the “Company”) appointed Richard Proud as the Company’s Chief Executive Officer (the “CEO”) and as a member of the Company’s Board of Directors (the “Board”).
Effective immediately upon Mr. Proud’s appointment as the CEO, the tenure of Robert Galvin as the Company’s Interim Chief Executive Officer concluded. Mr. Galvin will continue in his position as the Company’s Interim Chief Operating Officer.
As previously disclosed, Mr. D’Attanasio resigned from the Board, effective September 15, 2022.
On April 20, 2023, John Paterson was appointed to the board of directors (the “Board”) of iAnthus Capital Holdings, Inc. (the “Company”), as well as to the Audit Committee of the Board (the “Audit Committee”).
Effective as of February 21, 2023, Zachary Arrick resigned as a member of the board of directors (the “Board”) of iAnthus Capital Holdings, Inc.
Max materiality 0.85 · Median 0.60 · Most common event earnings